For this reason, identification of specific biomarkers for the early assessment of cancer response can help personalized cancer therapy based on the cancer responsiveness to a prescribed regimen.
Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.
Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition.
The model mirrors observations of breast cancer response and histopathological changes to tamoxifen in neo-adjuvant trials.
Our results highlight that a biomimetic tumoral niche enables to reveal potent cellular effects and so far hidden molecular mechanisms underlying the breast cancer response to chemokines.
Furthermore, we propose environmental stress response biomarkers as platform readouts for the efficient control and further prediction of the pancreatic cancer response to the environmental and treatment input.
In this work we present a comprehensive computational framework to help in the clinical assessment of cancer response from a pair of time consecutive oncological PET-CT scans.
Our goal was to determine the prognostic significance of FDG-PET assessment of rectal cancer response to preoperative chemoradiation.
CONCLUSIONS: Our results indicate that FDG-PET assessment of locally-advanced rectal cancer response to preoperative chemoradiation may predict longterm outcomes.
Furthermore, 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT), a positron emitting thymidine derivative, is often used to monitor cancer response towards chemotherapy (Tehrani and Shields 2013).
Padhani et al. [13] also reported that the change in the range of tumor perfusion and permeability estimated by MRI was able to predict breast cancer response to treatment, indicating that intra-tumoral heterogeneity is important.
